Corporate News Report
Spruce Biosciences (SPRB) – A Mid‑Market Biotech Focused on Endocrinology
On Wednesday, 21 October 2026, Spruce Biosciences shares traded up by 1.89 % during the 24‑hour period that ended at 08:36 AM Central Europe time. The most recent trading price stood at USD 41.23 on major exchanges, reflecting a modest lift from the previous close.
Trading Activity and Market Position
- Current Market Capitalisation: USD 114 million
- Shares Outstanding: 2.9 million
- Volume in the Last 24 Hours: Approximately USD 2.3 million worth of shares were exchanged.
The stock’s performance over the preceding month has been negative, registering a decline of 24.77 % since the end of September. Over a longer horizon, the simple moving average calculated over the past 200 days sits at USD 57.37, indicating that the current price is below its historical mean and suggesting potential for further downward movement or a rebound.
Historical Price Extremes
- 52‑Week High: USD 144, reached on 22 October 2025
- 52‑Week Low: USD 38.06, recorded on 14 October 2026
These figures illustrate a broad range of volatility, with the current price positioned closer to the lower end of the 52‑week span.
Peer Performance Snapshot (Last 24 Hours)
| Stock | % Change | Current Price (USD) | Market Capitalisation (USD million) |
|---|---|---|---|
| Hooker Furnishings (HOFT) | –1.17 % | 12.84 | 136.1 |
| Quanterix (QTRX) | –3.48 % | 2.72 | 135.7 |
| Canton Strategic (CNTN) | –0.29 % | 1.73 | 135.1 |
| Codexis (CDXS) | +6.45 % | 1.23 | 135.8 |
| Maxcyte (MXCT) | 0 % | 1.43 | 134.2 |
Spruce Biosciences is therefore trading in a sector that is largely experiencing modest declines, with the exception of Codexis, which has seen a notable gain.
Company Overview
Spruce Biosciences, Inc. is a biotechnology firm headquartered in Daly City, United States, that specialises in the development of endocrinology and orphan drugs. Its pipeline aims to address unmet medical needs for patients suffering from endocrine disorders across the country. The company’s public listing is on the Nasdaq stock exchange, and further details on its research programmes and commercial strategy are available on its website at www.sprucebiosciences.com .
This concise snapshot captures the current market dynamics surrounding Spruce Biosciences, providing investors and analysts with a clear picture of its recent performance, relative position within the industry, and key metrics that may inform future trading decisions.